(RTTNews) - Endo International plc (ENDP) Friday said its subsidiary, Endo Ventures Limited has entered into deal with Quoin Pharmaceuticals Inc. (QNRX) to develop and sell the latter's QRX003 in Canada.
QRX003, a topical lotion formulated with a proprietary delivery technology, is Quoin's lead product for Netherton syndrome, a rare congenital skin disorder.
If the product is approved, Paladin Labs Inc., an operating company of Endo, will do all commercial activities in Canada, Endo said in a statement.
In April this year, Quoin had received clarence from the FDA to initiate clinical studies for its Investigational New Drug application for QRX003.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
